Ascentage Pharma Group International American Depository Shares (AAPG)

About AAPG

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic ma…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

828

Website

www.ascentage.cn/

Fundamentals

1-day range

$17.73$18.28

Market cap

$1.57B

P/E (trailing)

—

P/E (forward)

-13.56

EPS (trailing)

$-3.49

Dividend yield

—

Beta

0.76

Avg. volume

10.8K

Forecasts

9 analyst ratings

Ascentage Pharma Group International American Depository Shares Competitors

Chosen by industry and closest market cap.

• AAPG

  Ascentage Pharma Group International American Depository Shares

  $18.28

  ▼ 2.16%
  Market cap $1.57BP/E —
  $30$91.5
• INVA

  Innoviva Inc. Common Stock

  $20.97

  ▲ 0.05%
  Market cap $1.53BP/E 4.21
  $16.52$25.15
• TRAX

  First Tracks Biotherapeutics Inc. Ordinary Shares

  $41.77

  ▼ 6.64%
  Market cap $1.61BP/E —
  $14.72$49.91
• PAHC

  Phibro Animal Health Corporation Class A Common Stock

  $37.64

  ▲ 3.55%
  Market cap $1.51BP/E 14.51
  $28.25$60.08
• MRVI

  Maravai LifeSciences Holdings Inc. Class A Common Stock

  $7.67

  ▼ 8.42%
  Market cap $1.66BP/E —
  $2.28$9.42
• HROW

  Harrow Inc. Common Stock

  $37.23

  ▼ 3.40%
  Market cap $1.46BP/E —
  $28.54$54.85
• BCAX

  Bicara Therapeutics Inc. Common Stock

  $23.42

  ▼ 5.70%
  Market cap $1.69BP/E —
  $10.3$30.99

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• 12 Health Care Stocks Moving In Thursday's Pre-Market Session
  Benzinga · 8/27/2026
• BTIG Reiterates Buy on Ascentage Pharma Group, Maintains $48 Price Target
  benzinga · 8/21/2026
• BTIG Reiterates Buy on Ascentage Pharma Group, Maintains $48 Price Target
  Benzinga · 8/21/2026
• Transcript: Ascentage Pharma Group H1 2026 Earnings Conference Call
  Benzinga · 8/21/2026
• Ascentage Pharma Group International (AAPG) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/20/2026
• Ascentage Pharma Group International 2026 Q2 - Results - Earnings Call Presentation
  SeekingAlpha · 8/20/2026
• Reported Earlier, Ascentage Pharma Group H1 EPS $(0.32) Beats $(0.44) Estimate, Sales $44.541M Beat $24.070M Estimate
  Benzinga · 8/20/2026
• CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
  Yahoo · 8/5/2026
• Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
  Yahoo · 8/5/2026

• Zhai Yifan · May 21, 2026 · Option Exercise

  95.6K
• Zhai Yifan · May 21, 2026 · Option Exercise

  92.7K
• Yang Dajun · May 21, 2026 · Option Exercise

  92.7K
• Yang Dajun · May 21, 2026 · Option Exercise

  95.6K
• Yang Dajun · May 20, 2026 · Grant

  298.2K
• Yang Dajun · May 20, 2026 · Grant

  298.2K
• Zhai Yifan · May 20, 2026 · Grant

  103.4K
• Yang Dajun · May 20, 2026 · Grant

  92.7K
• Yang Dajun · May 20, 2026 · Grant

  103.4K
• Yang Dajun · May 20, 2026 · Grant

  215.0K
• Yang Dajun · May 20, 2026 · Grant

  215.0K
• Yang Dajun · May 20, 2026 · Grant

  103.4K
• Yang Dajun · May 20, 2026 · Grant

  95.6K
• Zhai Yifan · May 20, 2026 · Grant

  298.2K
• Zhai Yifan · May 20, 2026 · Grant

  298.2K

Institutional Ownership

March 31, 2026

Total shares held

30.2K

Total value held

$721.7K

Institutional holders

7